FGFR1 and cancer: Similarly, by candidate-gene or comprehensive genomic analyses, other actionable targets were identified as cetuximab-resistance biomarkers, including MET Proto-Oncogene and Fibroblast Growth Factor Receptor 1 (FGFR1) amplification [46, 96], ERBB2 and MAP2K1 activating mutations [46, 97], insulin Like Growth Factor 2 (IGF2) overexpression [98], and the fusion of echinoderm microtubule-associated protein-like 4 (EML4) gene with the anaplastic lymphoma kinase (ALK) gene leading to the production of a protein (EML4-ALK) that promotes and maintains the malignant behavior of the cancer cells [99].